Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer.
Gupta S, Strohbehn IA, Wang Q, Hanna PE, Seethapathy R, Prosek JM, Herrmann SM, Abudayyeh A, Malik AB, Loew S, Carlos CA, Chang WT, Beckerman P, Mithani Z, Shah CV, Renaghan AD, de Seigneux S, Campedel L, Kitchlu A, Shin DS, Coppock G, Lumlertgul N, Garcia P, Ortiz-Melo DI, Rashidi A, Sprangers B, Aggarwal V, Benesova K, Jhaveri KD, Cortazar FB, Weins A, Zuo Y, Mooradian MJ, Reynolds KL, Leaf DE, Sise ME; ICPi-AKI Consortium.
Gupta S, et al. Among authors: leaf de, de seigneux s.
Kidney Int. 2022 Oct;102(4):930-935. doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11.
Kidney Int. 2022.
PMID: 35964800
Free PMC article.
No abstract available.